NRSN

+ Watchlist + Portfolio

NeuroSense Therapeutics Ltd.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.05
52-Week Range: $3.82 – $26.64
Market Cap: $7.46M
P/E (TTM): —
EPS (TTM): -47.10
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -2174.98%
Return on Assets: -247.30%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.31
Debt/Equity: —
Total Debt: $170.00K
Free Cash Flow: $-3.87M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $6.96M

NRSN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$5.59M	$7.27M	$5.70M	$6.23M
Selling, General & Admin	$4.97M	$4.78M	$4.20M	$4.86M
Operating Expenses	$10.55M	$12.05M	$9.90M	$11.09M
Operating Income	-$10.55M	-$12.05M	-$9.90M	-$11.09M
EBITDA	-$10.54M	-$12.03M	-$9.88M	-$11.07M
Pretax Income	-$10.49M	-$10.11M	-$10.21M	-$11.13M
Net Income	-$10.49M	-$10.11M	-$10.21M	-$11.13M
Diluted EPS	-0.91	-0.74	-0.54	-0.44
Diluted Shares	11.50M	13.64M	18.91M	25.48M

NRSN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$3.54M	$2.64M	$3.38M	$166.00K
Receivables	$131.00K	$166.00K	$164.00K	$33.00K
Current Assets	$7.38M	$2.92M	$4.40M	$778.00K
Total Assets	$7.71M	$3.19M	$4.58M	$1.03M
Current Liabilities	$1.73M	$3.46M	$1.99M	$2.52M
Total Debt	$211.00K	$142.00K	$73.00K	$170.00K
Total Liabilities	$2.09M	$4.94M	$1.99M	$2.59M
Retained Earnings	-$20.79M	-$26.12M	-$36.66M	-$47.78M
Shareholders' Equity	$5.62M	-$1.76M	$2.58M	-$1.56M
Working Capital	$5.66M	-$543.00K	$2.41M	-$1.74M

NRSN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$7.62M	-$8.35M	-$10.13M	-$7.67M
Capital Expenditure	-$70.00K	-$29.00K	-$3.00K	-$8.00K
Free Cash Flow	-$7.69M	-$8.38M	-$10.14M	-$7.68M
Depreciation & Amortisation	$12.00K	$21.00K	$22.00K	$16.00K
Stock-Based Compensation	$1.73M	$1.54M	$557.00K	$2.14M
Investing Cash Flow	-$3.59M	$3.47M	$1.00K	-$8.00K
Financing Cash Flow	$3.77M	$3.98M	$10.91M	$4.43M
Net Change in Cash	-$7.43M	-$911.00K	$779.00K	-$3.25M

NRSN Income statement, quarterly periods, in USD
USD	Q4 2024	Q2 2025	Q4 2025
Revenue	$0.00	—	—
Research & Development	$1.09M	—	—
Selling, General & Admin	$685.00K	—	—
Operating Expenses	$1.77M	—	—
Operating Income	-$1.77M	—	—
EBITDA	-$1.77M	—	—
Pretax Income	-$1.80M	—	—
Net Income	-$1.80M	—	—

NRSN Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q2 2025	Q4 2025
Cash & Equivalents	—	$666.00K	$166.00K
Receivables	—	$847.00K	$33.00K
Current Assets	—	$1.56M	$778.00K
Total Assets	—	$1.68M	$1.03M
Current Liabilities	—	$2.20M	$2.52M
Total Debt	—	—	$170.00K
Total Liabilities	—	$2.20M	$2.59M
Retained Earnings	—	-$41.37M	-$47.78M
Shareholders' Equity	—	-$519.00K	-$1.56M
Working Capital	—	-$647.00K	-$1.74M

Market Snapshot

About

NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology company developing treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company focuses on combination therapies targeting multiple pathways involved in neuronal death. NeuroSense is advancing its lead candidate PrimeC through clinical trials for ALS patients.